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Candida tropicalis is a diploid ascomycetes yeast re-
sponsible for 4%–24% of candidemia. Resistance to ﬂ  ucy-
tosine is rarely described for this species but was observed 
for 45 (35%) of 130 C. tropicalis isolates recovered from 
blood cultures in the Paris area in a 4-year survey. The aims 
of this study were to test the hypothesis that the ﬂ  ucyto-
sine-resistant isolates could represent a subgroup and to 
determine the relationship between epidemiologic and ge-
nomic data. Epidemiologic data and gene sequences were 
analyzed, and molecular typing was performed. Our results 
suggest that a clone of ﬂ  ucytosine-resistant isolates, asso-
ciated with malignancies and a lower mortality than that for 
other C. tropicalis isolates, is widespread in the Paris area. 
We propose the analysis of 2 polymorphic microsatellite 
markers coupled with URA3 sequencing to track the clone.
C
andida tropicalis is a diploid ascomycetes yeast com-
monly found on the skin and in digestive tracts of 
healthy human hosts worldwide (1). Infections caused by 
C. tropicalis are reported in 4%–24% of patients with can-
didemia, depending on the country of study, underlying risk 
factors, and period of study (2). Primary resistance to ﬂ  ucy-
tosine (5FC) occurs in <5% of all Candida species except 
for C. krusei, in which it is detected in up to 28% of iso-
lates (3). It was thus unexpected to observe 35% resistance 
to 5FC among C. tropicalis isolates recovered from blood 
cultures in the active surveillance program on yeast-related 
fungemia implemented by the French National Reference 
Center for Mycoses and Antifungals (NRCMA) in the 
Paris area. The YEASTS program is designed to analyze 
the epidemiologic trends of yeast fungemia by collecting 
isolates and epidemiologic and clinical data. The second 
objective is to study the clinical isolates in terms of species, 
antifungal susceptibility proﬁ  les, and genetic diversity to 
look for associations between subtypes of isolates and epi-
demiologic/clinical parameters. To test the hypothesis that 
the 5FC resistant (R5FC) isolates could represent a differ-
ent species or a subgroup, the R5FC and susceptible (S5FC) 
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isolates were compared on the basis of several phenotypic 
and molecular features.
Materials and Methods
Strains
Clinical isolates of C. tropicalis recovered from blood 
cultures during the YEASTS program from October 1, 
2002, through September 30, 2006, were selected for the 
study. Epidemiologic and clinical data concerning the pa-
tients were collected by using a standardized electronic 
form. Isolates (1 isolate/patient) were sent to NRCMA for 
identiﬁ  cation and MIC determination (see below). All iso-
lates were stored frozen in 40% glycerol at –80°C.
The type strain of C. tropicalis CBS 94 (ATCC 750, 
S5FC) was included in the study as a reference. In addi-
tion, 29 strains of taxonomic synonyms available at the 
Centraalbureau voor Schimmelcultures (CBS, Utrecht, the 
Netherlands) were studied.
Phenotypic Characterization of All 
C. tropicalis Isolates
All isolates were identiﬁ  ed at the species level by us-
ing the assimilation patterns obtained with the commercial-
ized strips ID32C (bioMérieux, Marcy-l’Etoile, France). 
MICs to 9 systemic antifungal agents were determined for 
all clinical isolates and the type strain by using the EU-
CAST microdilution method (4). For nonclinical isolates, 
only MICs of 5FC and ﬂ  uconazole were determined.
Additional Studies on Selected Isolates
Growth Characteristics
For the ﬁ  rst 16  S5FC and 14 R5FC consecutive iso-
lates of C. tropicalis and for CBS 94 other studies were 
performed. Additional carbon sources were tested by us-
ing the commercial strips CH50 (bioMérieux). Maximal 
temperature of growth (42°C or 45°C) was determined on 
Sabouraud dextrose agar. Growth in hyperosmolar medium 
(50% glucose or 10% NaCl) was also evaluated.
Nucleotide Sequence Determination
After 24 hours of incubation at 27°C on Sabouraud 
agar plates, single colonies were discharged in 1 mL of 
distilled water in a microcentrifuge tube, and DNA extrac-
tion was performed by using the High Pure PCR Template 
Preparation Kit (Roche Applied Science, Mannheim, Ger-
many) according to manufacturer’s instructions. Universal 
fungal primers were used for the ampliﬁ  cation of the inter-
nal transcribed spacer 1 (ITS1)–5.8S-ITS2 (primers V9D 
and LS266 [5,6]) and the 26S (primers NL1 and NL4 [7]) 
rDNA regions. Primers (Table 1) were designed to amplify 
a partial sequence of the actin gene (GenBank accession 
nos. AJ389059 and AJ508499) and the 14-α-demethylase 
gene (GenBank accession nos. AY942646 and M23673). 
Reaction volumes of 20 μL contained 1 μL of genomic 
DNA, 1.25 U of AmpliTaq Gold, 2 L of PCR buffer 10×, 
2 μL of 25 mmol/L MgCl2 2 μL of 2.5 mmol/L deoxy-
ribonucleoside triphosphates (dNTPs) (Roche), and 1 μL 
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Table 1. Primers sequences and amplification parameters used in the present study 
Locus Primer  5ƍ labeling  Sequence (5ƍ ĺ 3ƍ)*
 
Annealing 
temperature, °C 
14ĮDM†  DMC1   >TGGGTGGTCAACATACTTC  50 
 DMC2‡    <CATCTRTGTCTACCACCACC   
Actin ACTa    >AAGGTATTATGGTTGGTATGG  55 
 ACTb    <TCGAAATCTAAAGCAACGTAA   
URA3 URAF  HEX§
  >ATTGGATAGTCCCTCTAAACTCACTACTA 55 
 URAr    <AGCATTAGTTATATCACTCCACGATGAA  
 URAF2    >TGCCGATATTGGAAATACAGTTA  50 
 URAr2    <AATCAACTATTCAAGTTGACCG   
 CTU2    <GTTGGAACATCAATTGATGCACATAAAT  55 
Unknown CT14a 6FAM¶  >GTAAATCTTGTATACCGTGGA  55 
 CT14b    <TAGCCCATTTTCTAGTTTTGC   
FCY1 CTCDf   >ATCATTAGTTCAGATGGTAAAGTCTTG  58 
 CTCDr    <CCTTTTTAGTAACATGTCTATTCTCCA   
FCY2 CTCP1f   >TGCCCATAAATTAAATGCAGAA  58 
 CTCP1r    <GGAAGCAACAAACCCAAAAA   
FCY2 CTCP2f   >TGCTGCCGATTATGTTGTTT  58 
 CTCP2r    <GTGAAAACGAGCCAATCCAT   
FUR1 FUR1f   >TCATCAAAACCATGTCTGCTG  58 
 FUR1r    <AAGTGTATGTAGTGATAATTGCTATGC   
*>, Sense primer; <, antisense primer. 
†14 Į demethylase. 
‡R = G or A. 
§4, 7, 2ƍ,4ƍ, 5ƍ,7ƍ-hexachloro-6-carboxyfluorescein. 
¶6-carboxyfluorescein. Flucytosine-Resistant Candida tropicalis
(10 μM) of primers. The PCR products were ampliﬁ  ed by 
using the ICycler Thermocycler (Bio-Rad, Marnes-La-Co-
quette, France) set up with a ﬁ  rst cycle of denaturation for 
10 min at 95°C, followed by 30 cycles of denaturation at 
94°C for 30 s, 30 s at the relevant annealing temperature, 
elongation at 72°C for 30 s, and a ﬁ  nal extension step of 10 
min at 72°C. Both strands of puriﬁ  ed ampliﬁ  ed fragments 
were sequenced at the Genopole of the Pasteur Institute, on 
an ABI Prism 3700 DNA Analyzer (Applied Biosystems, 
Courtaboeuf, France), with the same primers that were 
used in the PCR step. Sequences were edited with Chro-
mas Pro version 1.33 (Technelysium Pty Ltd, Helensvale, 
Queensland, Australia). Multiple sequences alignments 
were performed with Clustal W version 1.8 (www.ebi.
ac.uk/clustalw/).
Following preliminary results, primers were then de-
signed to amplify the complete sequence of the orotidine-
5′-phosphate decarboxylase gene (URA3, GenBank acces-
sion no. AF040702) (Table 1). Furthermore, the complete 
sequences of FCY1 (coding for the cytosine deaminase), 
FCY2 (coding for the purine cytosine permease), and FUR1 
(coding for the uracil phosphoribosyl transferase) were 
determined. Primers were designed by using sequences 
from the Broad Institute C. tropicalis database genome (lo-
cus CTRG_02927.3 for FCY1, locus CTRG_02059.3 for 
FCY2, and locus CTRG_02689.3 for FUR1) (Table 1). The 
sequences were ampliﬁ  ed as described above (except for 
the duration of annealing and elongation [1 min] when us-
ing the primers set CTCP1f/CTCP1r). The sequences were 
translated with the standard genetic code (www.bioinfor-
matics.org/sms/index.html). The resulting protein sequenc-
es were aligned with the BioloMICS software (BioloMICS, 
version 7.2.5, BioAware S.A., Hannut, Belgium).
Microsatellite Selection
C. tropicalis genome sequences available from Gen-
Bank databases and from the Broad Institute (www.broad.
mit.edu/annotation/fungi/candida_tropicalis) were studied 
to identify sequences containing microsatellite repeats. 
Two polymorphic microsatellite markers (PMMs) were 
selected, 1 upstream of the URA3 gene (URA3 PMM) 
and 1 on a nonannotated sequence (CT14 PMM). Oligo-
nucleotide primers were designed from the sequence of 
the corresponding ﬂ  anking regions to obtain PCR products 
ranging in size from 100 bp to 200 bp. One primer of each 
set was 5′ labeled with different dyes (Table 1). PCR was 
conducted independently for the 2 loci in a 20-μL reaction 
volume containing 2 μL of extracted DNA, 1.25 U of Am-
pliTaq Gold, 2 μL of PCR Buffer 10×, 4 μL of 25 mmol/L 
MgCl2 , 2 μL of 2 mmol/L dNTPs, and 0.2 μL (10 μM) of 
primers. PCR ampliﬁ  cations were performed for a total of 
27 cycles by using the following conditions: denaturation 
at 95°C for 30 s, annealing at 55°C for 30 s, extension at 
72°C for 1 min, and a ﬁ  nal extension step of 5 min at 72°C. 
Two microliters of each PCR product mixed with 20 μL 
of formamide and 0.5 μL of an internal standard labeled 
with 6-carboxy-X-rhodamine dye (GeneScan-500 Tamra, 
Applied Biosystems) was run on an ABI Prism 310 Ge-
netic Analyzer (Applied Biosystems). Sizes of the allele 
and PCR fragments were determined with GenScan 3.0 
(Applied Biosystems, Weiterstadt, Germany). To assign a 
speciﬁ  c length to a PCR fragment, all electromorphs were 
aligned with that of the type strain (CBS 94). Each allele 
was named after the length of PCR fragments. Isolates for 
which 1 signal was observed for a given locus on the elec-
tromorph were considered homozygous for this locus by 
analogy with what is reported for another diploid yeast, C. 
albicans (8).
Multilocus Sequence Typing Analysis
Three of the 6 MLST loci recently described were 
analyzed as reported in Tavanti et al. (9). These loci were 
selected because, according to these authors, they were as-
sociated with more polymorphism (XYR1 and SAPT4) and 
with antifungal resistance (MDR1). Both strands of puriﬁ  ed 
ampliﬁ  ed fragments were sequenced, and sequences were 
edited as described above. Heterozygosity was deﬁ  ned 
by the presence of 2 coincident peaks of similar height 
in the forward and the reverse sequence chromatograms. 
The 1-letter code for nucleotides from the nomenclature 
of the International Union of Pure and Applied Chemis-
try (IUPAC, www.bioinformatics.org/sms/iupac.html) was 
used. Sequences were compared with the allele sequences 
of the C. tropicalis MLST database (www.pubmlst.org/
ctropicalis). For each gene, distinct alleles were identiﬁ  ed 
and numbered by using the Internet-based MLST program 
(www.mlst.net). New alleles were submitted to the MLST 
C. tropicalis database.
Statistical Analysis
In accordance with French regulations, the clinical 
database was approved by the Commission Nationale de 
l’Informatique et des Libertés. Information concerning de-
mographic data, risk factors for candidiasis, and outcome 
30 days after the diagnosis of fungemia were recorded. 
We considered 3 groups of patients according to the in-
fecting isolate: S5FC, R5FC that belong to the clone (R5FC 
clone, see below), and R5FC that do not belong to the clone 
(termed “other R5FC”). The sociodemographic and clini-
cal characteristics were compared between the 3 groups 
of isolates by using the Fisher exact test. The χ2 Armitage 
trend test (10) was used to assess a trend in the evolution of 
the R5FC clone’s proportion among resistant strains across 
years of study. Multinomial logistic regression (11) ad-
justed on clinical center was used to investigate the factors 
associated with infection by the R5FC clone or other R5FC 
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isolates compared to S5FC isolates according to sociodemo-
graphic and clinical characteristics. A logistic regression 
model adjusted on clinical center was also performed to 
identify the factors associated with the acquisition of the 
R5FC clone compared with other R5FC isolates. Regression 
models were constructed by using the backward procedure. 
First, all covariates with a p value <0.25 in univariate mod-
els were simultaneously entered into the regression model. 
The set of covariates with the largest p value was itera-
tively removed from the model until all of the covariates 
(or blocks of covariates) remaining in the reduced model 
had a p value <0.05. Statistical analyses were performed 
with Stata software, version 9.0 (StataCorp, College Sta-
tion, TX, USA).
Results
Phenotypic Characterization of R5FC Isolates
We analyzed the episodes of fungemia caused by 
C. tropicalis and recorded during the ﬁ  rst 4 years of the 
YEASTS study; 130 episodes were recorded in 24 of the 
27 participating centers. Distribution of ﬂ  ucytosine MICs 
showed 2 populations, 1 with MICs <2 μg/mL and 1 with 
MICs >8 μg/mL (Figure). In light of these results, suscepti-
bility to 5FC (S5FC) was deﬁ  ned by an MIC <8 μg/mL and 
resistance (R5FC) by an MIC >8 μg/mL.
The proportion of R5FC isolates (45 [35%]) of the 130 
isolates) was uneven, ranging from 0% to 67% of the iso-
lates, depending on the center of isolation. However, the 
proportion of R5FC isolates did not differ over the study 
period (data not shown). We ﬁ  rst studied the characteristics 
of a subset of 16 S5FC and 14 R5FC C. tropicalis isolates 
(strain CBS 94 had all the characteristics of S5FC clinical 
isolates described below but is not included in the analy-
sis). There was no difference in terms of growth in hyper-
osmolar media between R5FC and S5FC clinical isolates. 
By contrast, R5FC and S5FC isolates differed in the propor-
tion of isolates growing at 45°C (40% vs. 100%, p<0.001) 
and assimilating starch (12.5% vs. 50%, p = 0.054) and 
xylitol (62.5% vs. 12.5%, p = 0.009). No difference in the 
MIC of azoles or caspofungin was noted. All 29 strains of 
C. tropicalis synonyms stored at the CBS exhibited 5FC 
MICs <0.5 μg/mL.
Genotypic Characterization of R5FC Isolates
This subset of isolates (16 S5FC and 14 R5FC) was 
further analyzed. The deletion of 1 nucleotide (A) in po-
sition 106 (according to the type strain sequence, Gen-
Bank accession no. AY939810) of the ITS2 region was 
observed in 14 (100%) of the 14 R5FC isolates compared 
to 5 (32%) of the 16 S5FC isolates (p<0.001) (GenBank 
accession no. EU288196). No difference in nucleotide se-
quences was found for the D1/D2 region of the 26S rDNA 
or in the portion of the 14-α demethylase (490 bp) and ac-
tin (550 bp) genes analyzed. PMM results are summarized 
in Table 2. The URA3 and CT14 PMM led to 6 and 7 dif-
ferent allelic associations, respectively. The association 
of both markers led to 13 PMM proﬁ  les. The 14 R5FC iso-
lates had the same URA3/CT14 PMM proﬁ  le; however, 
among the 16 S5FC, 15 had a PMM proﬁ  le different from 
that of the R5FC, and 1 (ODL6–560) had the R5FC PMM 
proﬁ  le. All but 1 (ODL2–237) of the R5FC isolates had 
the same MLST proﬁ  le, whereas none of the S5FC isolates 
exhibited the same combination of the 3 MLST studied. 
The entire URA3 nucleotidic sequence of the translated 
region was identical except in 1 position (GenBank ac-
cession no. EU288194 for the type strain CBS 94 and 
EU288195 for 1 of the R5FC isolates). S5FC isolates were 
either homozygous or heterozygous at position 529 (A-A 
or A-G), whereas all the R5FC isolates were homozygous 
G-G. This produced a change of K177E (lysine → gluta-
mate) for the R5FC isolates.
Thus, results obtained with nucleotide changes (dele-
tion of A in position 106 in the ITS2 region, mutation in 
position 529 of the URA3 gene) and polymorphisms in 3 
MLST and 2 PMMs suggested that the 14 R5FC studied 
were clonal. We thus decided to use the 2 PMMs (URA3 
PMM, CT14 PMM) to genotype all the C. tropicalis iso-
lates recovered during the study period in the YEASTS 
program. Of the 130 C. tropicalis isolates (including the 
30 isolates studied above), 45 were R5FC (Table 3). Thirty-
three different proﬁ  les were observed when both PMMs 
were combined for the 130 isolates. Among the 45 R5FC, a 
total of 29 isolates exhibited the proﬁ  le associated with the 
R5FC clone; 16 were different, with 11 different proﬁ  les, 6 
of which were shared with S5FC isolates. Among the S5FC 
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Figure. Distribution of 130 Candida tropicalis isolates recovered 
from blood cultures during the ﬁ  rst 4 years of an active surveillance 
program (YEASTS study) on yeasts fungemia in the Paris area, 
France (October 2002 through September 2006), according to the 
MICs of ﬂ   ucytosine determined with the EUCAST microdilution 
method (4).Flucytosine-Resistant Candida tropicalis
isolates, 4 had the PMM proﬁ  le associated with the R5FC 
clone. The URA3 gene was sequenced for these 4 isolates, 
and none had a G in position 529.
We then studied genes potentially involved in the 
mechanisms of 5FC resistance. For the FUR1 sequences, 
no missense mutation was observed, and the complete cod-
ing sequence of the type strain CBS 94 (GenBank accession 
no. EU327978) was similar to the sequence of the R5FC 
clone; however, a few silent mutations were observed in 
a few S5FC isolates (GenBank accession nos. EU327979, 
EU327980, and EU327981). Concerning the cytosine 
deaminase sequences (FCY1), only 1 silent mutation, 
C21T, occurred for the R5FC clone (GenBank accession 
no. EU327982). Finally, for the purine cytosine permease 
(FCY2), the sequences of the type strain (GenBank acces-
sion no. EU327983) and of the R5FC clone were similar. A 
few heterozygosities were observed for the S5FC isolates 
(GenBank accession nos. EU327984 and EU327985), but 
all these mutations were silent.
Factors Associated with Fungemia Caused 
by the C. tropicalis R5FC Clone
All 130 isolates corresponded to incident fungemia in 
different persons. The R5FC clone was recovered during the 
4 years of study with a trend toward a decreased proportion 
over time (11/13 [85%], 6/10 [60%], 8/13 [61.5%], and 4/9 
[44%]) during the ﬁ  rst, second, third, and fourth year of the 
study, respectively; p = 0.06). The proportion of the clone 
also varied across clinical centers (data not shown). Fac-
tors associated with fungemia caused by the R5FC clone 
of C. tropicalis were analyzed (Table 4). The proportion 
of patients infected by the R5FC clone was signiﬁ  cantly 
higher among patients with malignancies but their death 
rate was signiﬁ  cantly lower than for patients infection with 
other R5FC or S5FC isolates. Multinomial logistic regres-
sion was adjusted by clinical centers to investigate the fac-
tors associated with infection by the R5FC clone or others 
R5FC isolates compared with S5FC isolates. The risk of 
being infected by the R5FC clone compared with a S5FC 
isolate signiﬁ  cantly increased in case of malignancy (odds 
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Table 2. Comprehensive analysis of 30 Candida tropicalis isolates*
PMM alleles  MLST 
Strain no. 
5FC MIC 
(Pg/mL) 
Month of
isolation
SNP
ITS2 URA3 CT14 MDR1 XYR1 SAPT4
URA3
base 529
ODL1–18 >64 2002  Nov  – 178/178 148/151 20 26 10 G
ODL1–40 >64 2002  Nov  – 178/178 148/151 20 26 10 G
ODL1–41 >64 2002  Nov  – 178/178 148/151 20 26 10 G
ODL1–53 16 2002  Dec  – 178/178 148/151 20 26 10 G
ODL2–105 >64 2003  Mar  – 178/178 148/151 20 26 10 G
ODL2–198 32 2003  Jul  – 178/178 148/151 20 26 10 G
ODL2–199 >64 2003  Jul – 178/178 148/151 20 26 10 G
ODL3–237 >64 2003  Sep  – 178/178 148/151 18 26 10 G
ODL3–293 >64 2003  Oct  – 178/178 148/151 20 26 10 G
ODL4–311 >64 2003  Sep  – 178/178 148/151 20 26 10 G
ODL4–328 >64 2003  Nov  – 178/178 148/151 20 26 10 G
ODL4–341 >64 2003  Nov  – 178/178 148/151 20 26 10 G
ODL5–426 >64 2003  Dec  – 178/178 148/151 20 26 10 G
ODL6–558 32 2004 Apr  – 178/178 148/151 20 26 10 G
ODL1–58 <0.125 2003  Jan + 176/176 148/148 24 30 7 A
ODL3–211 0.25 2003  Jul + 174/178 148/148 1 79 1 A-G†
ODL3–231 <0.125 2003  Sep  – 176/176 151/151 66 91 8 A
ODL4–302 0.25 2003  Sep  – 176/178 148/151 4 36 23 A
ODL4–347 0.25 2003  Nov  + 174/174 151/154 7 52 6 A
ODL4–384 0.5 2003  Dec  – 174/176 151/151 67 41 9 A
ODL5–460 <0.125 2004  Feb  + 174/178 148/148 68 76 36 A-G†
ODL5–474 <0.125 2004  Mar  + 174/174 154/154 7 52 6 A
ODL5–476 <0.125 2004  Mar  + 178/178 151/151 27 4 11 A
ODL5–485 <0.125 2004  Mar  – 176/178 148/157 22 41 7 A
ODL5–488 <0.125 2004  Apr  + 176/178 148/151 25 24 7 A
ODL6–504 <0.125 2004  Feb  + 174/178 148/151 22 9 38 A
ODL6–511 <0.125 2004  Apr  + 174/178 148/148 1 80 1 A-G†
ODL6–521 <0.125 2004  May  + 176/178 148/151 69 77 41 A
ODL6–539 <0.125 2004  Mar  + 174/174 148/154 58 48 13 A
ODL6–560 <0.125 2004  Jul  – 178/178 148/151 4 36 23 A
CBS94 <0.125 – + 176/176 148/148 70 78 5A
*5FC, flucytosine; SNP, single nucleotide polymorphism; ITS2, internal transcribed spacer 2; PMM, polymorphic microsatellites marker; MLST, multilocus 
sequence typing (boldface corresponds to new alleles). 
†A-G heterozygous. RESEARCH
ratio [OR] 3.7, 95% conﬁ  dence interval [CI] 1.4–10.1, p 
= 0.009), and the risk for death at day 30 after fungemia 
was signiﬁ  cantly decreased in patients infected by the R5FC 
clone compared with the S5FC isolates (OR 0.3, CI 0.1–0.9, 
p = 0.04), while no independent factor accounted for infec-
tion by other R5FC isolates versus an S5FC isolate. The only 
independent factor associated with infection by the R5FC 
clone compared with other R5FC isolates was the death rate 
at day 30 (OR 0.1, CI 0.03–0.6, p = 0.006).
Discussion
The bimodal distribution of 5FC MICs against C. 
tropicalis isolates prospectively collected from 27 differ-
ent clinical centers in the Paris area (YEASTS program, 
Figure) suggested that the C. tropicalis population was 
heterogenous. On the basis of physiologic characteristics 
and molecular analysis (nucleotide sequences of the ITS re-
gions, D1/D2 region of the large subunit, and large portions 
of the actin and 14-α-demethylase genes showing >99% 
similarity), we ﬁ  rst assessed a subset of isolates (the ﬁ  rst 
consecutive 14 R5FC and 16 S5FC isolates) and determined 
that both populations belong to the same species.
All 14 R5FC isolates had a single nucleotide deletion in 
position 106 of the ITS2 region, although 5 of the 16 S5FC 
isolates harbored it. When additional genotypic markers 
were used, all 14 R5FC isolates had the same allelic combi-
nation for 2 PMMs selected (URA3 and CT14), the same 
missense mutation in the URA3 gene, and the same diploid 
sequences for the 3 MLST loci studied. By contrast, only 1 
of 16 S5FC isolates had the same PMM proﬁ  les as the R5FC 
isolates, but this isolate differed in its MLST proﬁ  le and 
the lack of mutation in the URA3 gene. In addition, the 16 
S5FC isolates exhibited 16 different MLST and 12 different 
PMM proﬁ  les. This ﬁ  nding suggested the existence of a 
R5FC clone, but the rest of the population was genetically 
diverse. We thus analyzed the 130 isolates of C. tropicalis 
collected over 4 years in the YEASTS program by using 
the 2 PMMs and sequenced the URA3 gene when the PMM 
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Table 3. Distribution of the polymorphic microsatellites markers (PMM) profiles among 130 Candida tropicalis isolates, according to 
their susceptibility to flucytosine (5FC)* 
Allelic association  No. isolate types 
URA3 PMM  CT14 PMM 
Total no. isolates 
(N = 130)  S5FC (n = 85)  R5FC clone (n = 29)  Other R5FC (n = 16) 
172/172 142/148 3 3 – –
172/172 148/154 2 2 – –
172/174 142/148 3 2 – 1
172/174 148/148 1 1 – –
172/174 148/154 1 1 – –
172/176 142/148 5 4 – 1
174/174 142/148 5 3 – 2
174/174 148/148 1 – – 1
174/174 148/151 1 1 – –
174/174 148/154 6 6 – –
174/174 151/154 1 1 – –
174/174 154/154 1 1 – –
174/176 142/148 6 6 – –
174/176 148/151 1 1 – –
174/176 151/151 3 3 – –
174/178 142/148 8 5 – 3
174/178 145/151 1 – – 1
174/178 148/148 5 5 – –
174/178 148/151 2 1 – 1
176/176 142/148 11 10 – 1
176/176 148/148 3 3 – –
176/176 148/151 4 4 – –
176/176 151/151 1 1 – –
176/178 142/148 33 – –
176/178 145/151 1 1 – –
176/178 148/148 1 – – 1
176/178 148/151 5 5 – –
176/178 148/157 1 1 – –
176/180 151/151 1 1 – –
178/178 142/148 3 2 – 1
178/178 145/151 6 3 – 3
178/178 148/151 33 4 29 –
178/178 151/151 1 1 – –
*S subscript, susceptible; R subscript, resistant.Flucytosine-Resistant Candida tropicalis
proﬁ  le was identical to that of the 14 R5FC isolates previ-
ously studied. We discovered that 29 (64%) of 45 R5FC 
isolates had an identical PMM proﬁ  le (R5FC clone), while 
11 and 30 different PMM proﬁ  les were found among the 
other 16 R5FC isolates and the 85 S5FC isolates, respective-
ly. According to these data, we assumed that these 29 R5FC 
isolates were clonal or at least highly genetically related.
The proportion of 35% of C. tropicalis isolates resis-
tant to 5FC is unusual (3). Other studies report between 0 
(12) and 15% (13) with intermediate values (14–16), and 
all the isolates stored as C. tropicalis in the CBS collec-
tion since 1912 exhibited 5FC MIC <0.5 μg/mL. When we 
started the YEASTS program in 2002, the proportion of 
R5FC was already at 46% and the clone accounted for 85% 
of the R5FC isolates. The trend test suggested that the dis-
persal of the clone is declining in the Paris area. Whether 
this decline is speciﬁ  c for blood isolates or is a geographi-
cally and temporally restricted phenomenon deserves eval-
uation by using isolates collected over time from various 
body sites and geographic areas. An old report on isolates 
collected from various regions of France established with a 
nonstandardized technique that as many as 70% of the 63 
isolates tested had an MIC >32 μg/mL in the 1980s (17), 
and a recent study from Germany on clinical isolates recov-
ered from various body sites including blood reported that 
58.3% of isolates were resistant (18). Whether any of these 
isolates belong to the R5FC clone would be of interest. Of 
note, a recent study of 104 C. tropicalis clinical isolates 
recovered from various countries (9) showed that none of 
the 5 R5FC isolates collected in the United Kingdom has the 
MLST proﬁ  le of the R5FC clone.
In the univariate analysis, patients infected by the S5FC 
or R5FC isolates or by the R5FC clone differed signiﬁ  cantly 
in terms of proportion of underlying malignancies (high-
er in patients with the clone) and death rate 30 days after 
fungemia (lower for patients infected by the clone). The 
R5FC isolates as a whole, and the R5FC clone speciﬁ  cally, 
were unevenly distributed around the Paris area. When 
adjusted for clinical center, logistic regression analysis 
showed that, compared to infection by S5FC isolates, no 
factor was independently associated with infection by R5FC 
isolates other than the clone, whereas 2 parameters were as-
sociated with infection by the clone. Indeed, malignancies 
multiplied the risk of being infected by the clone by almost 
4 and the risk for death was divided by 3 in case of infec-
tion with the clone. C. tropicalis fungemia, independent of 
susceptibility to ﬂ  ucytosine, has already been associated 
with hematologic malignancies (19,20) (unpub. data from 
the YEASTS group). Whether the R5FC clone is less viru-
lent, as established for C. albicans isolates with decreased 
susceptibility to 5FC, remains to be determined (21).
The resistance to 5FC was associated with the K177E 
mutation in the URA3 gene in the clone. The mechanism 
of 5FC action is a consequence of intrafungal formation 
of 2 metabolites, 5-ﬂ  uorodeoxyuridine monophosphate and 
5-ﬂ  uorouridine triphosphate, which alter DNA and protein 
synthesis (22). The URA3 enzyme (orotidine 5′-phosphate 
decarboxylase, ODCase) is involved in the metabolic path-
way of uridyl-monophosphate (UMP), which is a substrate 
of thymidylate synthetase and UMP kinase, both involved 
in nucleic acid synthesis. This mutation involves an amino 
acid already known to be variable among reference strains 
(e.g., ATCC 20336), but it has not been associated with 
modiﬁ  cation of the URA3 properties thus far (T. Noël, 
pers. comm.). Nevertheless, this mutation could, for ex-
ample, modify the tridimensional structure of the protein, 
thereby affecting the binding afﬁ  nity of the substrate for the 
catalytic site and thus modifying the ODCase efﬁ  cacy. The 
ODCase is not known to interfere directly with 5FC ac-
tivity. However, one of the resistance mechanisms against 
5FC consists in increasing the transcription of all the genes 
involved in the de novo pyrimidine biosynthetic pathway 
(including URA3) to overproduce UMP (23).
The K177E mutation is associated with a speciﬁ  c 
PMM upstream the gene, with a possible role in the level of 
transcription. The fact that this PMM is homozygous may 
be due to a loss of heterozygosity. This phenomenon has 
been recently reported for C. albicans and the resistance 
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Table 4. Patient characteristics according to the 3 categories delineated by the susceptibility of the Candida tropicalis isolates to 
flucytosine (5FC)and their belonging to the R5FC clone* 
Characteristic S5FC (n = 85)  R5FC clone (n = 29)  Other R5FC (n = 16)  p value† 
>60 y of age  39 (46)  17 (59)  9 (56)  0.452
Male 55 (65)  18 (62)  10 (63)  0.962
Had malignancies  41 (48)  22 (76)  9 (56)  0.033
  Cancerous  15 (18)  7 (24)  5 (31)  0.374
  Hematologic  26 (31)  15 (52)  4 (25)  0.082
In intensive care unit  44 (52)  12 (41)  4 (25)  0.116
Had central venous catheter  68 (80)  24 (83)  12 (75)  0.894
Had recent surgery  27 (32)  8 (30)  4 (25)  0.918
Had prior antifungal therapy  11 (13)  0 2 (13)  0.093
Died before day 30  34/81 (42)  6/28 (21)  10/15 (67)  0.014
*S subscript, susceptible; R subscript, resistant. Values are no. (%). 
†Fisher exact test. RESEARCH
to azoles (24) and for a speciﬁ  c C. albicans isolate and the 
resistance to caspofungin (25).
The mutations described in the 5FC resistance of C. 
albicans (26) or C. lusitaniae (27) involved 3 major genes: 
FCY2 coding for the purine cytosine permease, which en-
ables 5FC to enter the fungal cell; FCY1 coding for the 
cytosine deaminase, which transforms 5FC into 5FU; and 
FUR1 coding for the uracil phosphoribosyl transferase, 
which transforms 5FU into 5FUMP. The fact that the clone 
was susceptible to 5FU suggests that the 5FC resistance 
could result from a mutation in the cytosine deaminase, the 
cytosine permease, or both (23). However, the sequences 
of the R5FC clone, some S5FC isolates, and the type strain 
CBS94 did not show any mutation in coding sequences 
of FCY1, FCY2, or FUR1 susceptible to explain the resis-
tance of the clone to 5FC. The mechanism explaining the 
possible relationship between the speciﬁ  c PMM (URA3 
178/178 and CT14 148/151), the K177E mutation, and the 
resistance to 5FC remains to be determined.
Our results suggest that a clone of R5FC isolates re-
sponsible for fungemia is widespread among patients hos-
pitalized with malignancies in the Paris area and is associ-
ated with a lower mortality than that of other C. tropicalis 
isolates. Despite a trend toward a decreased proportion 
over time, further studies are needed to assess this clone’s 
geographic and temporal distribution. Analysis of the 2 
PMMs described in this study, coupled with determination 
of nucleotide at position 529 in the URA3 gene, should pro-
vide reliable means to track this clone.
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